5J90.F Fluicell AB (publ)

Healthcare Biotechnology Frankfurt Exchange
2.44 EUR
Close of Nov 11, 2026
0.7200 5.22
Market cap
EUR 3.35M
P/E
12.8x
P/B
2.26x
ROE
67.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5J90.F undervalued?

Graham number
Price2.44
Graham value2.15
Premium13.6%

5J90.F trades 13.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fluicell AB (publ) fundamental analysis

No fundamental analysis for Fluicell AB (publ) yet.

Fluicell AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fluicell AB (publ)

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion chann…

Full company profile